All In Biotech

Drug Trial Radar · NCT06754930

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

A Multicenter, Open Phase IB/II Clinical Study of Safety, Tolerability, and Efficacy of SHR-1826 in Combination With Other Anti-cancer Treatment in Patients With Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 18, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • SHR-1826Drug

    SHR-1826 for injection.

  • SHR-1316Drug

    SHR-1316 for injection.

  • SHR-9839Drug

    SHR-9839 for injection.

  • SHR-8068Drug

    SHR-8068 for injection.

  • Ametinib mesylateDrug

    Ametinib mesylate.

  • BP-102Drug

    BP-102 for injection.

  • CarboplatinDrug

    Carboplatin for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase II dose (RP2D)Time frame: Screening up to study completion, an average of 1 year.
  2. Adverse events (AEs)Time frame: Screening up to study completion, an average of 1 year.
  3. Objective response rate (ORR)Time frame: Screening up to study completion, an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.